Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...

A cardiologist spotlights cardiac amyloidosis, a protein disease often mistaken for hypertension. Learn the signs and how to get screened.

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in patients taking widely used rhythm-control medications such as flecainide, which ...